pcf-39 has been researched along with Diabetes-Mellitus--Type-2* in 1 studies
1 other study(ies) available for pcf-39 and Diabetes-Mellitus--Type-2
| Article | Year |
|---|---|
In vitro response to mitogens and antigens in elderly and post-cytotoxic patients can be modified by a new hypoxanthine derivative (PCF-39).
The in vitro immunomodulatory properties of the hypoxanthine derivative N alpha-5(1.6-dihidro-6-oxo-9-purinyl)pentyloxy/carbonyl -L-arginine (PCF-39) are described. Data obtained with PHA in vitro indicate that PCF-39 exhibits immunopharmacologic activity in elderly and post-cytotoxic patients, while showing no significant activity in normal donors. Antigen induced proliferation was unaffected by PCF-39, while PMN induced chemiluminescence was significantly enhanced. PCF-39 can be considered a new drug in the family of the hypoxanthine derivatives endowed with immunomdulatory properties. Topics: Aged; Aging; Antineoplastic Agents; Arginine; Diabetes Mellitus, Type 2; Humans; Hypoxanthines; Immunity, Cellular; Lymphocyte Activation; Melanoma; Phytohemagglutinins | 1987 |